Q-omics provides the consensus-scored ABHD11 profile across patient tissues and cancer cell-line models. ABHD11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ABHD11 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ABHD11 protein abundance shows 27,790 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where ABHD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD11 survival associations across molecular data types. ABHD11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD11 RNA expression–survival associations across cancer types. High ABHD11 expression shows unfavorable associations in UVM, UCEC, LAML, LGG and STAD, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ABHD11 RNA expression.
This table summarizes ABHD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD11 shows higher tumor expression in COAD, STAD, LUAD, KIRP, LIHC and UCEC. The COAD box plot shows higher ABHD11 RNA expression in tumor versus normal tissue (log2 FC = +0.772, t-test p < 0.001).
This table shows molecular features associated with ABHD11 in patient tissues and cancer cell lines. In patient samples, ABHD11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
